Identification of Luminal Subtypes of Breast Carcinoma Using Surrogate Immunohistochemical Markers and Ascertaining Their Prognostic Relevance
- 1 October 2020
- journal article
- research article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 20 (5) , 382-389
Abstract
No abstract availableKeywords
Funding Information
- Tata Memorial Centre
This publication has 30 references indexed in Scilit:
- Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013Journal of Breast Cancer, 2015
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular MarkersBMC Medical Genomics, 2012
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancerCancer Science, 2012
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working GroupJNCI: Journal of the National Cancer Institute, 2011
- Molecular Classification of Breast Carcinomas by Immunohistochemical AnalysisDiagnostic Molecular Pathology, 2009
- Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?Annals of Oncology, 2005
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001
- MIB-1 labelling index is an independent prognostic marker in primary breast cancerBritish Journal of Cancer, 1998